Mechanisms of inherited cancer susceptibility

A small proportion of many cancers are due to inherited mutations in genes, which result in a high risk to the individual of developing specific cancers. There are several classes of genes that may be involved: tumour suppressor genes, oncogenes, genes encoding proteins involved in DNA repair and cell cycle control, and genes involved in stimulating the angiogenic pathway. Alterations in susceptibility to cancer may also be due to variations in genes involved in carcinogen metabolism. This review discusses examples of some of these genes and the associated clinical conditions caused by the inheritance of mutations in such genes.

[1]  H. Järvinen,et al.  Impact of screening examinations on survival in familial adenomatous polyposis. , 2000, Scandinavian journal of gastroenterology.

[2]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[3]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[4]  P. Propping,et al.  TO JMG A genotype-phenotype correlation in HNPCC : strong predominance of msh 2 mutations in 41 patients with Muir-Torre syndrome , 2004 .

[5]  Siân Jones,et al.  Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH , 2003, The Lancet.

[6]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[7]  A. Viel,et al.  Germ Line Mutations of Mismatch Repair Genes in Hereditary Nonpolyposis Colorectal Cancer Patients with Small Bowel Cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study , 2006, Clinical Cancer Research.

[8]  Douglas Easton,et al.  Variation in BRCA 1 Cancer Risks by Mutation Position 1 , 2002 .

[9]  S. T. N. Arod.  Prophylactic mastectomy in carriers of BRCA mutations. , 2001 .

[10]  M. Ilyas,et al.  THE INTERACTIONS OF APC, E‐CADHERIN AND β‐CATENIN IN TUMOUR DEVELOPMENT AND PROGRESSION , 1997, The Journal of pathology.

[11]  D. Easton,et al.  Variation in BRCA1 cancer risks by mutation position. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[13]  P. Watson,et al.  The Tumor Spectrum in the Lynch Syndrome , 2004, Familial Cancer.

[14]  P. Johnston,et al.  BRCA1: mechanisms of inactivation and implications for management of patients , 2002, The Lancet.

[15]  K. Offit,et al.  Prophylactic mastectomy in carriers of BRCA mutations. , 2001, The New England journal of medicine.

[16]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[18]  P. Møller,et al.  MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  O. Sieber,et al.  Genomic instability — the engine of tumorigenesis? , 2003, Nature Reviews Cancer.

[20]  P. Propping,et al.  A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome , 2004, Journal of Medical Genetics.

[21]  B. Ponder,et al.  Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. , 1996, Cancer research.

[22]  P. L. Chen,et al.  Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. , 1988, Science.

[23]  P. Peltomäki,et al.  Mutations Associated with HNPCC Predisposition — Update of ICG-HNPCC/INSiGHT Mutation Database , 2004, Disease markers.

[24]  J. Garber,et al.  Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer. , 2003, Gastroenterology.

[25]  Anne,et al.  BREAST CANCER AFTER PROPHYLACTIC BILATERAL MASTECTOMY IN WOMEN WITH A BRCA 1 OR BRCA 2 MUTATION , 2001 .